Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInventory AverageInvested Capital

Zhengye Biotechnology Holding (ZYBT) Equity Average (2024 - 2025)

Zhengye Biotechnology Holding has reported Equity Average over the past 2 years, most recently at $47.1 million for Q4 2025.

  • Quarterly Equity Average fell 2.07% to $47.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $47.1 million through Dec 2025, down 2.07% year-over-year, with the annual reading at $41.4 million for FY2025, 3.8% down from the prior year.
  • Equity Average was $47.1 million for Q4 2025 at Zhengye Biotechnology Holding, down from $50.0 million in the prior quarter.
  • Over five years, Equity Average peaked at $50.0 million in Q2 2025 and troughed at $47.1 million in Q4 2025.